Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) that has come back or stopped responding to treatment
• People whose cancer cells test positive for a protein called CD30, confirmed by a certified pathology laboratory
• People whose blood hemoglobin level is at least 7.0 (including after a blood transfusion)
• People who are generally able to carry out normal daily activities, as measured by a standard functioning score (called a Karnofsky or Lansky score above 60%)
• People aged 16 to 75 (or 12 to 75 once the trial site has confirmed the dose level is safe at that range)
• People whose liver function tests (bilirubin and AST) are within acceptable ranges
• People whose kidneys are filtering at an acceptable level (estimated GFR above 70 mL/min)
• People whose blood oxygen level is above 90% while breathing normal air
• People with no significant irregular heart rhythms shown on a heart tracing (EKG)
• People who have recovered from the non-blood-related side effects of previous chemotherapy
• People with adequate lung function, as measured by standard breathing tests
• People whose blood cells collected for the trial show a sufficient level of the modified immune cells needed for treatment (at least 15% CD30CAR expression)
• People who are willing to use effective contraception during the study and for 6 months afterward; male partners are also asked to use a condom
• People who have had the trial explained to them and have signed a consent form (a parent or guardian may sign for younger patients)

Who may not be able to join:

• People who are currently infected with HIV or HTLV (at the tissue collection stage, results may still be pending)
• People who have an active bacterial, fungal, or viral infection
• People who are currently taking part in another clinical trial or have received a cancer vaccine within the past 6 weeks
• People who have received a treatment targeting the CD30 protein within the past 4 weeks
• People whose cancer is progressing very rapidly and did not respond to the most recent chemotherapy
• People with very large tumours — specifically, a mass of 10 cm or more, or a chest tumour exceeding a certain size relative to the chest
• People with a history of allergic reactions to products containing mouse-derived proteins
• People who are pregnant or breastfeeding
• People who have a tumour located where swelling could block the airway
• People currently taking corticosteroids (such as prednisone) at a daily dose of 0.5 mg/kg or higher
• People with active bleeding in the bladder (haemorrhagic cystitis)
• People with significant heart disease affecting daily functioning (confirm with trial site for exact classification)

Important: Always verify eligibility with the trial site directly before applying.